DexCom Inc (DXCM)

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using InsulinJune 6, 2026 2:45 PM
Business Wire Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260606323066/en/ “The CONNECT study released today is the first and only level A evidence demonstrating strong benefit of CGM for the Type 2 non-insulin using population,” said Roy Beck, MD, PhD, medical director of the JAEB Center for Health Research and senior author of the study. “Level A evidence, the highest level of evidence graded by the ADA, has historically driven meaningful changes in standards of care.” CONNECT demonstrated clinically significant benefit for all adult Type 2 non-insulin using patients regardless of age, gender, ethnicity, baseline A1C, body mass index, education level, income and insurance coverage.1 The study also showed an additional clinically significant reduction in A1C when using Dexcom G7 with various combinations of current standards of care diabetes medication, including metformin, GLP-1s and SGLT2s.1 “We anticipate these results will help establish a new standard of care in the US and around the world,” said Jake Leach, president and CEO of Dexcom. “This is the third Dexcom sponsored randomized controlled trial that has, or will drive, Dexcom CGM to be the standard of care in people with Type 2 diabetes.” All CONNECT study participants were provided diabetes education on diet and exercise at the start of the study, given a blood glucose meter, and pre-study glucose lowering medications were continued. Half of the study participants were put on Dexcom G7 and half of them used self-monitoring of blood glucose. The CONNECT study initially screened 440 participants across 22 primary care practices throughout the United States, of which 283 eligible participants were randomized to Dexcom G7 or routine care, with 265 completing the 26-week study and analyzed for the key outcomes reported at ADA. Key outcomes from the study include1: Average 1.6% A1C reduction with Dexcom G7 from baseline mean A1C of 8.8%. Participants using Dexcom G7 experienced on average a 1.6% A1C reduction at 26 weeks, representing a 0.9% greater A1C reduction compared to the control group. Participants using Dexcom G7 with an initial A1C >10% experienced on average a 3.1% A1C reduction, representing a 2.1% greater A1C reduction compared to the control group. 82% of participants had a clinically and statistically significant lower A1C of at least 0.5%. 68% of participants using Dexcom G7 reached

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User ExperienceJune 2, 2026 9:30 AM
Business Wire Company establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its technology and reinforce its leadership as the premier choice for people with diabetes, globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602604976/en/Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Formed in January 2026, the Dexcom Customer Advisory Council brings together a diverse group of stakeholders – people with Type 1 and Type 2 diabetes, caregivers, diabetes educators, healthcare professionals and community advocates from around the world – to create a direct and ongoing dialogue with the people who depend on Dexcom products every day. "Dexcom has pioneered and set the global standard for continuous glucose monitoring, and we are deeply committed to continually raising that standard to meet the evolving needs of our community," said Jake Leach, president and chief executive officer of Dexcom. "This council represents our belief that the best path forward is through listening – truly hearing what's working and what isn't. We will continue to be transparent, responsive and relentless in our pursuit of earning and maintaining the trust of our users every day." Through independent moderation by Vital Findings, council members reinforced that Dexcom remains a life-changing, essential technology that has improved millions of lives. They also identified opportunities to improve product reliability, customer service and communication, prompting six concrete commitments outlined in the report: Delivering the best possible product by continuously improving the performance of every Dexcom sensor. Making sure product replacements are easier, replacing any sensor confirmed as a product failure without limit and offering self-service ways to request replacements. Raising the bar for customer service, making the experience more human, informed and responsive. Making the Customer Advisory Council a permanent part of how Dexcom does business. Communicating more clearly and transparently, including product updates, company news and issues (good or bad). Creating a new content series that demystifies the science and technology behind CGM. The council will continue to meet throughout 2026, with regular public updates on progress against commitments. The full Customer Advisory Council Community Commitment Report, including in-depth discussions on accuracy, connectivity, adhesives and more, is available at dexcom.com/about-dexcom. Toward the end of 2026, Dexcom will announce the format and approach for the continuation of the Customer Advisory Council in 2027 and beyond. About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com. 1 Dexcom, Data on File, 2025 View source version on businesswire.com: https://www.businesswire.com/news/home/20260602604976/en/ Media Contact
James McIntosh

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted UsersMay 26, 2026 9:30 AM
Business Wire Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market. Dexcom is working closely with the FDA and other authorities to ensure patient safety and to investigate the crime. DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company’s quality control process. Sensors identified as scrap are sent to a third-party vendor for destruction and recycling. At this time, Dexcom has identified two lots of Dexcom G7 sensors (1725204004 and 1725069002) that were stolen, sold and used by some customers. “Nothing matters more to Dexcom than the safety of our users and maintaining the trust of the diabetes community,” said Jake Leach, president and CEO of Dexcom. “We are treating this matter with the utmost seriousness and are working closely with regulators and other authorities to ensure user safety, determine exactly how this product was stolen and hold the perpetrators fully accountable for their crimes.” Dexcom traced sales of this stolen product back to Pharmsource, LLC, who is not an authorized Dexcom distributor but supplies some independent pharmacies and DME distributors in the United States. Pharmacies that purchased product from Pharmsource should take extra care to review their inventory. Dexcom is notifying customers directly across numerous communication channels. This issue primarily impacts the US, therefore communication to US customers will precede communication to OUS customers. Users with sensors from affected Dexcom G7 lots (1725204004 and 1725069002) should not use those sensors and can call Dexcom Customer Support in the US at 1-844-478-1600 to request replacements. More information on how to determine if sensors are from an affected lot and what action to take is available at www.dexcom.com/theft-check. Dexcom is working to update this website with resources for users outside the US and will notify those users as soon as it is updated. Dexcom's authorized distributors provide Dexcom G7 sensors to the largest pharmacy retailers and medical distributors in the United States and around the world. Pharmacy retailers and medical distributors who receive Dexcom product from authorized Dexcom distributors are not impacted. Educational samples are also not impacted. The authorized US Dexcom distributor list can be found at www.dexcom.com/dexcom-suppliers. Potential harm associated with stolen product Lot 1725204004: Dexcom G7 sensors that are not properly sterilized have an increased risk of skin infection. Lot 1725069002: Dexcom G7 sensors from a lot with an elevated internal testing failure rate have an increased risk of having no sensor readings available. There have been no reported severe adverse events associated with the stolen product. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260526622391/en/ Media Contact
James McIntosh
959-716-6698
james.mcintosh@dexcom.com Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com Original: Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in GermanyMay 18, 2026 7:31 AM
Business Wire Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom Flex provides real-time glucose data, personalised behavioural insights, and simplified tracking tools to support informed decision-making. DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518266091/en/ Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. Dexcom Flex reflects the company’s commitment to placing people at the centre of the product design process and creates a personalised diabetes guidance experience, rather than offering a one-size-fits-all approach. What is Dexcom Flex? Dexcom Flex is a continuous glucose monitoring system that provides users with 24/7 glucose readings on a smartphone, smartwatch† or receiver, without routine fingerpricks‡. The CGM system features: Real-time glucose monitoring with optional food and activity logging, developed to support people and their healthcare providers gain a clearer picture of how food, exercise, daily activities, and long-acting insulin impact glucose patterns. Optional and customisable low glucose alerts, designed to help prevent hypoglycemic events1. Personalised glucose insights created to aid users connect daily diet, activity and medication dosing decisions to glucose levels, supporting motivation and meaningful behaviour change. Dexcom Flex is designed to highlight the insights that matter most, supporting people to build confidence in understanding and responding to their glucose levels over time. “The development of Dexcom Flex reflects a shift toward personalised diabetes guidance” said Ian Hanson, senior vice president of engineering at Dexcom. “We strongly believe that personalised diabetes care is what helps people adopt the new habits and behavioural changes that lead to meaningful results. Dexcom Flex has been designed to support people earlier in their Type 2 diabetes journey, delivering a more tailored experience while maintaining the accuracy and reliability associated with Dexcom technology.” Why it matters Type 2 diabetes is a large and growing global health challenge with hundreds of millions of people living with the disease globally2. Many people not using intensive insulin therapy have historically had limited access to CGM technology. Germany is among the European countries expanding the use of digital health tools in Type 2 diabetes care. The introduction of Dexcom Flex is intended to support healthcare providers and healthcare systems in broadening access to CGM across more diverse patient groups. Studies have shown that CGM use in people with Type 2 diabetes may support reductions in diabetes-related hospitalisations*,3-4. The use of CGM is also associated with a reduction in long-term complications such as cardiovascular risks~ and reduced mortality in people with type 2 diabetes5-7. People with Type 2 diabetes have also reported that CGM use has improved their confidence, increased their understanding of the impact of food on their glucose levels#,8-10. Research has also shown that Dexcom CGM systems can help people with Type 2 diabetes using basal insulin reduce their HbA1c and increase the time spent in their target glucose range#,11. “Launching Dexcom Flex in Germany reflects our continued focus on expanding access to CGM.” said Alexander Fröhlich, vice president and general manager DACH at Dexcom. “As personalisation becomes increasingly important in Type 2 diabetes care, Flex enables a more tailored approach to glucose monitoring. By supporting people earlier in their Type 2 journey, before they require intensive insulin therapy, Flex may help improve long-term health outcomes and contribute to meaningful reductions in diabetes-related complications.” About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com For more information about Dexcom Flex, visit: https://www.dexcom.com/de-DE/fachpersonal † Simultaneous use of a compatible smartphone is required to receive readings on compatible smartwatch. ‡ Fingerpricks are required for diabetes treatment decisions if symptoms or expectations do not match readings. * Based on a retrospective analysis of administrative claims data from the Optum Research Database for patients with type 2 diabetes in the United States. ~ Cardiovascular risk refers to 10-year ASCVD risk. Visit https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ to access the American College of Cardiology ASCVD Risk Estimator Plus. # Results obtained with a previous generation Dexcom CGM system and are applicable to Dexcom Flex given similar feature sets, performance, and usability.
1 Dexcom Flex User Guide, 2025. 2 International Diabetes Federation: Diabetes Atlas – 11th Edition 2025. 2025. 1-130.
3 Norman GJ, et al. J Manag Care Spec Pharm. 2025;31(1):15-24. 4 Garg SK, et al. Diabetes Obes Metab.2024;26(11):5202-5210. 5 Reed J, et al. Diabetes Obes Metab. 2024;26(7):2881-2889. 6 Liu BCL, et al. Diabetes 2025;74(S1):202. 7 Reaven PD, et al. Diabetes Technol Ther. 2025:10.1089/dia.2025.0227 8 Crawford MA, et al. Diabetes. 2023;72(S1):63–LB. 9 Crawford MA, et al. Diabetes Technol Ther. 2025;27(S2):e193. 10 Crawford M, et al. Diabetes Technol Ther. 2024;26(S2):A223. 11 Martens T, et al. JAMA. 2021;325(22):2262-2272 View source version on businesswire.com: https://www.businesswire.com/news/home/20260518266091/en/ Allison for Dexcom
DexcomEMEA@allisonworldwide.com Original: Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Why Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 10:30 AM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).







Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointOther industry developments and happenings in the market include:Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio."The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance."Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction."Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes."There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html

Original: Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026March 11, 2026 2:00 AM
Business Wire

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations.



During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio.



Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus-based CGM competency framework to give healthcare professionals a clear, role-aligned structure for delivering confident, consistent CGM support.2



 


DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more details about future product features across its global portfolio at the upcoming 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11-14, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310854672/en/New evidence shows how Dexcom CGM can help improve long-term health and reduce hospitalizations across diabetes types.
“There is no better global stage than ATTD to showcase how we’re shaping the future of glucose biosensing around the world. This year's conference is especially meaningful for me as it marks my first major diabetes industry event as CEO," said Jake Leach, president and chief executive officer at Dexcom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin. That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.”


New evidence shows how Dexcom CGM can help improve long-term health and reduce hospitalizations across diabetes types1,3-4


Dexcom is presenting several abstracts during the annual conference showcasing clinical and real-world evidence that support the benefits of glucose biosensing. Key abstract highlights include:



One-year real-world impact of Dexcom CGM on HbA1c in non-insulin-treated Type 2 diabetes: evidence from U.S. primary care


A multi-center primary care registry showed that after one year of Dexcom G7 use, people with Type 2 diabetes not using insulin saw significant improvement in A1C and weight management, supporting the benefits and importance of access to Dexcom CGM for all people with Type 2 diabetes.1






Dexcom CGM initiation is associated with reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits in children and adults with Type 1 diabetes


Claims data reported lower DKA-related hospitalizations and ER visits with Dexcom CGM use. The results suggest the combination of Dexcom's real-time glucose readings and alerts are associated with significant reductions in DKA-related hospitalizations and ER visits in both children and adults with Type 1 diabetes.3






A prospective, multi-center study of a CGM-informed basal insulin therapy optimization system in people with Type 2 diabetes


A feasibility study revealed Dexcom Smart Basal was safe and effective for people with Type 2 diabetes starting or optimizing basal insulin therapy.4






Dexcom’s upcoming product roadmap and commitment to innovation and education


ATTD in-person and virtual attendees will have the opportunity to learn more about Dexcom’s continued innovation and commitment to improving CGM education by attending the following symposia and presentations:



Dexcom symposium: ‘Dexcom technology, innovation and clinical implications: Current portfolio, near and long-term vision’ – Thursday, March 12 from 2:40-4:10 p.m. CET, in 'Auditorium'.


Highlighting the company’s vision across its near-term product portfolio both for Dexcom products geared towards those with diabetes and the company’s move into the health and wellness sector with Stelo. Topics will include upcoming features in Dexcom G7 and Dexcom G7 15 Day, Dexcom ONE+, Stelo, Clarity and a high-level introduction to our next generation sensor.






Dexcom symposium: ‘Transforming diabetes care: The power of Dexcom CGM from prediabetes to insulin therapy’ – Friday, March 13 from 8:30-9:20 a.m. CET, in Hall 113, Level P1.


Showcasing the benefits of early CGM use in prediabetes, its role in optimizing therapy in Type 2 diabetes before insulin, and how Dexcom Smart Basal supports reliable and effective basal insulin initiation and titration.






E-poster: ‘A reference framework for CGM training and education among healthcare providers’ – Thursday, March 12th from 10:10 – 10:25 a.m. CET and Friday, March 13th from 10:45 – 11:00 a.m. CET, at the Dexcom booth, 14A Level P0.


Presenting the first consensus-based CGM competency framework to give healthcare professionals a clear, role-aligned structure for delivering confident, consistent CGM support, with Prof. Pratik Choudhary, Principle Author (Thursday) and Prof. Julia Mader, Primary Author (Friday). Dexcom is utilizing the framework, to deliver Dexcom Academy, the first HCP education platform guided by HCP insights. The Dexcom Academy platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands and Spain with further launches in Italy, Poland, Turkey, and Sweden planned throughout 2026. More information about, and live demonstrations of, the Dexcom Academy platform are available at the Dexcom booth, 14A, Level P0.






Dexcom’s presence at ATTD builds on the company’s recent retail launch of Dexcom G7 15 Day in the United States, further demonstrating the company’s leadership and continued commitment to driving forward product innovation, evidence generation and CGM education for the entire industry.


For more information about Dexcom presentations at ATTD and to register to virtually attend the conference, visit https://attd.kenes.com/.


About Dexcom


Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.


Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.


Category: IR



____________________



1 Martens T, et al. One-Year Real-World Impact of Dexcom CGM on HbA1c in Non-Insulin-Treated Type 2 Diabetes: Evidence From U.S. Primary Care Registry Analysis. Presented at ATTD 2026. 2 Mader J, et al. A Reference Framework for Continuous Glucose Monitoring Training and Education Among Healthcare Professionals. Presented at ATTD 2026. 3 Nemlekar P, et al. RT-CGM Initiation is Associated with Reductions in DKA-Related Hospitalizations and ER Visits in Children and Adults with Type 1 Diabetes. Presented at ATTD 2026. 4 Beck S, et al. A Prospective, Multi-center Study of a CGM-Informed Basal Insulin Therapy Optimization System in People with Type 2 Diabetes. Presented at ATTD 2026.







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310854672/en/
Media Contact

Nadia Conard

mediarelations@dexcom.com


Investor Contact

Sean Christensen

sean.christensen@dexcom.com


Original: Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

Dexcom Appoints Rick Osterloh to Board of DirectorsFebruary 26, 2026 4:15 PM
Business Wire
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026.


Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company’s portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google’s Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Under his leadership, Google has integrated its portfolio to align and accelerate the company’s advanced product capabilities across hardware, software and artificial intelligence. Mr. Osterloh brings to the Dexcom Board expertise in innovation oversight, strategic transactions and long-term strategic planning.


“Rick is highly respected as one of the most influential technology product leaders of our time,” said Jake Leach, president and CEO at Dexcom. “His insight into creating impactful, scalable products that integrate the latest innovative technologies aligns closely to Dexcom’s vision for long-term product development. We look forward to benefiting from Rick’s expertise as we advance our mission to improve the metabolic health for millions of people around the world.”


“I am honored to join the Dexcom Board at such an important moment for the company and for the future of metabolic health,” said Osterloh. “Dexcom’s leadership in biosensing aligns closely with my own passion for building and advancing technologies that address clear needs and improve people’s lives. I look forward to partnering with the Board and executive team to execute on the company’s compelling mission.”


About Rick Osterloh


Mr. Rick Osterloh serves as Senior Vice President, Platform & Devices at Google, leading a unified group spanning Android, Google Play, Chrome, and Google’s Devices & Services Portfolio (Pixel, Nest, Fitbit), a position he has held since 2016. Prior to this, Mr. Osterloh held additional senior leadership roles across consumer technologies. He served as President of Motorola Mobility from 2014-2016, and Senior Vice President, Product Management & GM Premium Products, Motorola Mobility from 2012-2014, overseeing global product strategy and operations during Motorola’s transition under Google and subsequently Lenovo. Prior to this, Mr. Osterloh served as Vice President, Product & Design at Skype from 2010-2012 and held earlier roles at Motorola, Amazon, Kleiner Perkins Caulfield & Byers and Deloitte.


Mr. Osterloh received bachelor’s and master’s degrees in Industrial Engineering from Stanford University. He also obtained an MBA from Stanford Graduate School of Business.


About DexCom, Inc.


Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.


Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.


Category: IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226231409/en/
Media Contact

James McIntosh

619-884-2118

mediarelations@dexcom.com


Investor Contact

Sean Christensen

858-203-6657

investor-relations@dexcom.com


Original: Dexcom Appoints Rick Osterloh to Board of Directors

Yes I am looking for $60.00..DXCM

TIMBER!!! will probably bottom out in the $40s

Grabbed a few as well…here’s to hope!

I grabbed some $63.09’s here today I hope I am not too early but I can add if need to and wait. Should be good for a bounce at some point.

Why is nobody talking about $TRIB. Trinity Biotech recently purchased DexCom Incs technology. $TRIB is a hidden gem

https://www.webcaster4.com/Player/Index?webcastId=41975&g=5ff46fae-ca0b-4696-b3a4-4a64d6dfc159&uid=3737459&sid=

I will

You think sens will disrupt, check out KNWN. They have not only a breakthrough platform for numerous non-invasive medical applications but the 60+ patents to secure their success.

SuperBowl commercial will reach huge multi million viewer audience to both educate about CGM, make Dexcom better known to potential audience and is part of "direct to consumer" or significantly ramped up DTC marketing program in preparation for the launch of G7 device later this year. If you check the job websites like LinkedIn,Indeed and monster.com you can see that huge hiring ramp of over 150 spots to increase manufacturing shifts in Arizona, add more detail teams to call on pharmacies and support additional future R&D efforts. The 12 months 8/21 to 8/22 are going to be explosive IMHO.

Get in below a buck? Yep I'd love to do that but......maybe another stock?

Upcoming presentation at update at JPMorgan Healthcare Conference may be a catalyst

I think it’s bc sens will disrupt that sector superior product 6 month product that is superior period. If you missed dxcm get in sens cause it makes cents to be in here below a buck

BREAKING NEWS: $DXCM Why Is No One Talking About DexCom Stock?

Glucose monitor maker DexCom (NASDAQ: DXCM) has had a rough month. After a Wall Street analyst downgraded the stock Oct. 2 and sharply trimmed its price target, the price fell over the next 30 days, with the majority of the downward movement taking place in the last week of Octo...

Got this from DXCM - Why Is No One Talking About DexCom Stock?

Just In: $DXCM Why I Just Bought These 2 Under-the-Radar Stocks

Last week, I bought shares of Dexcom (NASDAQ: DXCM) and Inari Medical (NASDAQ: NARI) . But while it's obvious to me that Dexcom is an incredibly successful stock, having run up almost 3,400% since its IPO 15 years ago, it still hasn't garnered a lot of investor attention. ...

Got this from DXCM - Why I Just Bought These 2 Under-the-Radar Stocks

what was reason for Wells Fargo analyst downgrade today?

Hmmm, probably whether you got in at $50 or $500 might influence you feelings these days... Great company, product, and big PPS.

The share price is supposed to go up.

I want a refund on my investment!

Trueheart

CNBC's Joshua Brown discussed DXCM today. He said it was priced high but given the need for its products he blessed it, along with other companies that produce medical devices. He mentioned Japan, Europe and America as being great markets.

He was asked if the stock was too high and his reply was it had a long runway and wouldn't bet against it.

Zounds!

Truehea

The beauty of DexCom is that it's growing because Americans are growing --- in size.

Diabetes is rampant and fat people continue to eat and seem not to give a damn that the disease is killing them slowly.

Onward and upward!

Trueheart

News: $DXCM Could DexCom Be a Millionaire-Maker Stock?

Winners tend to keep on winning. And make no mistake about it:  DexCom (NASDAQ: DXCM) is a winner. During its 21 years in business, the medical-device maker has transformed how individuals manage diabetes. DexCom's market cap now stands at close to $40 billion. The company generated nea...

Got this from DXCM - Could DexCom Be a Millionaire-Maker Stock?

Motley Fool just recommended DXCM today.

Not too big to avoid strategic acquisition by a Lilly or Johnson & Johnson

Wow, another 30% up. A winner that keeps on producing.

Great day here today...must be good news coming.

Nmrd has just recieved CE mark for sugar beat device , non invasive wireless CMG

Bought into this at 60 way back an still holding it. Hoping for split, never know peeps, $$$$$ patience

AAC, in New Orleans this coming weekend, has as one of its featured breakthrough presentations "the Apple Watch". We own DXCM shares here too, as well as AAPL shares.

I use their G6 and it is great product. Their customer service is one of the worst ever. Now, they are outsourcing it overseas where they know nothing about it? Geez.

Wow, outstanding Q and prospects for the rest of the year and beyond!

DXCM: Normal for diabetics.

https://www.webmd.com/diabetes/guide/normal-blood-sugar-levels-chart-adults

Just keeps climbing- nice

Short

Short

Great news for both the company and the world of diabetics!

DXCM: The reason:

http://ih.advfn.com/p.php?pid=nmona&article=77048172

Moving north very nicely....looking good!

HENDERSON GROUP PLC has filed a new 13G, reporting 10.2% ownership in $DXCM - https://fintel.io/i/henderson-group and https://fintel.io/i/henderson-group

fillin the gap..

DXCM RSI 5

DXCM RSI 5

....and now this ...

Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment"...

zagdad

Huge news for DexCom, its shareholders, and the patients in need IMHO.

zagdad